Scholarlink

Background <p>Immunotherapy combined with chemotherapy has become a standard first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC), but the efficacy of consolidative low-dose thoracic radiotherapy for patients receiving such treatment remains unclear. Furthermore, a notable feature of immunotherapy is that it may cause immune-related adverse events, including immune-related endocrine diseases.</p> Case Reports <p>We reported two cases from a Phase II clinical trial(ChiCTR2300079125): The treatment regimen consisted of four cycles of EC regimen chemotherapy combined with the PD-L1 inhibitor adebrelimab, followed by consolidative thoracic radiotherapy (30&#xa0;Gy) and subsequent maintenance therapy with adebrelimab. Both patients achieved partial remission, all patients achieved partial response with progression-free survival (PFS) of 16&#xa0;months or longer and one of them developed a rare immune checkpoint inhibitor-induced type 1 diabetes mellitus presenting as diabetic ketoacidosis and hypothyroidism.</p> Conclusions <p>Chemotherapy combined with immunotherapy plus low-dose thoracic radiotherapy has proven to be an effective treatment regimen in the cases we have reported. Meanwhile, safety concerns regarding immunotherapy, such as the rare occurrence of diabetic ketoacidosis, also warrant attention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Carboplatin and Etoposide in Combination with Adebrelimab Plus Low-Dose Thoracic Radiotherapy as First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: Case Series

  • 期刊论文

  • 发表日期：

    2026年4月9日

查看全文
  • Xiaofang Wang,
  • Zhuo Yang,
  • Chunlong Lin,
  • Shangfu Li,
  • Lingge Yang,
  • Shaohua Xu,
  • Li Xu,
  • Liang Yi

摘要

Background

Immunotherapy combined with chemotherapy has become a standard first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC), but the efficacy of consolidative low-dose thoracic radiotherapy for patients receiving such treatment remains unclear. Furthermore, a notable feature of immunotherapy is that it may cause immune-related adverse events, including immune-related endocrine diseases.

Case Reports

We reported two cases from a Phase II clinical trial(ChiCTR2300079125): The treatment regimen consisted of four cycles of EC regimen chemotherapy combined with the PD-L1 inhibitor adebrelimab, followed by consolidative thoracic radiotherapy (30 Gy) and subsequent maintenance therapy with adebrelimab. Both patients achieved partial remission, all patients achieved partial response with progression-free survival (PFS) of 16 months or longer and one of them developed a rare immune checkpoint inhibitor-induced type 1 diabetes mellitus presenting as diabetic ketoacidosis and hypothyroidism.

Conclusions

Chemotherapy combined with immunotherapy plus low-dose thoracic radiotherapy has proven to be an effective treatment regimen in the cases we have reported. Meanwhile, safety concerns regarding immunotherapy, such as the rare occurrence of diabetic ketoacidosis, also warrant attention.